Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Iroquois homeobox protein 6 (IRX6) is a member of the Iroquois homeobox gene family that encodes DNA-binding transcription factors regulating gene expression during development. IRX6 is primarily active in the nucleus, where it binds DNA to modulate transcription, leading to cell development, neuron differentiation, and retina morphogenesis. Dysregulation of IRX6 (such as through methylation or decreased expression) has been detected in multiple cancers, including colon, breast, and gastric cancer, where its status may serve as a prognostic biomarker. However, IRX6 is not currently recognized as a direct therapeutic target, nor are there drugs known to act specifically on this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Iroquois homeobox protein 6 (IRX6).